强化降压联合强化降脂治疗对冠心病患者心血管不良事件的影响被引量：5

导出

摘要目的探讨强化降压联合强化降低低密度脂蛋白胆固醇水平(LDL-C)能否进一步降低冠心病患者心血管不良事件风险。方法入选2009年1月至2010年1月249例原发性高血压合并高脂血症患者,采用随机对照临床研究的方法分为常规治疗组和强化治疗组。常规治疗目标为收缩压<140/90 mmHg,LDL-C<2.6 mmol/L;强化治疗目标血压<120/80 mmHg,LDL-C<2.1 mmol/L。比较主要终点事件:死亡、非致死性心肌梗死、脑卒中、血运重建和次要终点事件:再次心源性入院、不稳定性心绞痛、急性左心衰或短暂性脑缺血发作的组间差异。结果最终12个月共随访成功224例,常规治疗组114例,强化治疗组110例。与常规治疗组相比,强化治疗组患者随访6、12个月的收缩压和随访12个月的舒张压均明显更低〔(121.2±13.8)vs(125.1±14.1)mmHg,P=0.026;(118.9±13.2)vs(124.8±13.1)mmHg,P=0.008;且强化治疗组患者随访6、12个月的LDLC水平明显低于常规治疗组〔(2.16±0.18)vs(2.40±0.16)mmol/L,P=0.002;(2.32±0.09)vs(1.96±0.11)mmol/L,P=0.000。但两组主要终点事件和次要终点事件的发生率均无统计学差异。结论强化降压联合强化降脂药物治疗在1年的观察期内未能给冠心病患者带来更多获益。

作者珠勒皮亚.司马义陈玉岚布海力且木.买买提

机构地区新疆医科大学第一附属医院高血压科库尔勒市第一人民医院心内科

出处《中国老年学杂志》 CAS CSCD 北大核心 2013年第18期4409-4411,共3页 Chinese Journal of Gerontology

关键词冠状动脉粥样硬化性心脏病低密度脂蛋白胆固醇高血压强化治疗

分类号 R541.4 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献12

1Zanchetti A. Bottom blood pressure or bottom cardiovascular risk? How far can cardiovascular risk be reduced [J] . Hypertens, 2009 ; 27 ( 8 ) : 1509-20.
2Preiss D, Welsh P, Murray HM,et al. Fasting plasma glucose in non-dia- betic participants and the risk for incident cardiovascular events, diabe- tes,and mortality: Results from WOSCOPS 15-year follow-up [J]. Eur Heart J,2010 ;31 (10) : 123045.
3Miyauchi K, Daida H. Clinical significance of intensive lipid-lowering therapy using statins in patients with coronary artery disease:LDL-cho- lesterol : The lower, the better; is it true for Asians [ J ]. Circ J, 2010 ; 74 (8) :1718-30.
4Eber B, Lautsch D, Fauer C, et al. Can LDL-cholesterol targets be a-ehieved in a population at high risk? Results of the non-interventional study ACT Ⅱ [J]. Curr Med Res Opin,2012;28(9) :1447-54.
5Kostis WJ, Thijs L, Richart T,et al. Persistence of mortality reduction af- ter the end of randomized therapy in clinical trials of blood pressure-low- ering medications[ J]. Hypertension ,2010 ;56 (6) : 1060-8.
6Bailey JE, Hajjar M, Shoib B, et al. Risk factors associated with antihy- pertensive medication nonadherence in a statewide Medicaid population [ J ]. Am J Med Sci,2012 ; ( Epub ahead of print) : 1-6.
7邓捷,韩雅玲,王效增,荆全民,王守力,马颖艳.高密度脂蛋白胆固醇水平降低对非ST段抬高型急性冠状动脉综合征介入治疗预后的影响[J].中国介入心脏病学杂志,2008,16(5):251-254. 被引量：3
8Ogihara T, Kikuchi K, Matsuoka H, et al. The Japanese Society of Hyper- tension Guidelines for the Management of Hypertension ( JSH 2009 ) [ J]. Hypertens Res ,2009 ;32( 1 ) : 103-7.
9Mancia G, De Backer G, Dominiczak A, et al. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension : ESH-ESC Task Force on the Management of Arterial Hypertension [J]. J Hypertens, 2007;25(9) :1751-62.
10Ramjee V, Sperling LS, Jacobson TA. Non-high-density lipoprotein cho- lesterol versus apolipoprotein B in cardiovascular risk stratification:do the math[J]. J Am Coil Cardiol,2011 ;58(5):457-63.

二级参考文献15

1陈征,华琦.冠状动脉病变与血脂代谢异常的相关性[J].中国介入心脏病学杂志,2005,13(2):100-102. 被引量：9
2Lavie CJ, Milani RV. Shedding Light on High-Density Lipoprotein Cholesterol: The Post-ILLUMINATE Era. J Am Coll Cardiol,2008,51 ;56-58.
3Ford ES, Giles WH, Dietz WH, et al. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA,2002,287:356- 359.
4Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome : an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation, 2005,112:2735-2752.
5Roel MT, Fang-Shu Ou, Karen P, et al. Patterns and prognostic implications of low high-density lipoprotein levels in patients with non-ST-segment elevation acute coronary syndromes. Eur Heart J, 2008,0 : ehnvi-9.
6Chapman M J, Assmann G, Fruchart JC, et al. Raising high- density lipoprotein cholesterol with reduction of cardiovascular risk : the role of nicotinic acid a position paper developed by the European Consensus Panel on HDL-C. Curt Med Res Opin, 2004,20 : 1253-1268.
7Gordon DJ, Rifkind BM. High-density lipoprotein the clinical implications of recent studies. N Engl J Med, 1989,321 : 1311- 1316.
8Castelli WP, Garrison RJ, Wilson PW, et al. Incidence of coronary heart disease and lipoprotein cholesterol levels: the Framingham Studv..IAMA. 1986. 256, 2835-2838.
9Olsson AG, Schwartz GG, Szarek M, et al. High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial. Eur Heart J, 2005,26:890-896.
10Roswitha MW, Brewer HB, Zhenyi Xue, et al. Impact of low high-density lipoproteins on in-hospital events and one-year clinical outcomes in patients with non-ST-elevation myocardial infarction acute coronary syndrome treated with drug-eluting stent implantation. Am J Cardiol, 2006,98:711-717.